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Background: Hepcidin is a 25 aminoacid peptide that is 
produced primarily by the liver in response to a variety 
of stimuli known to modulate tissue iron stores and its 
serum availability. It circulates in plasma, is filtered by 
the kidney, and accumulates in urine. The presence of 
hepcidin in the plasma negatively regulates the egress of 
iron from the cells and macrophages, involved in 
transport of iron into the extracellular spaces. Hepcidin 
binds to ferroportin 1 present on the cell surface leading 
to the internalization of ferroportin 1 and subsequent 
degradation.  Hepcidin has also been shown to be an 
acute phase reactant increased by interleukin6 (IL-6) and 
markedly induced by infection and inflammation. 
Documentation of the role of hepcidin in the 
development of anemia in chronic kidney disease and 
whether it can be used as a marker of iron status in 
chronic kidney disease (CKD) has been sought in many 
studies. 
The aim of this study was to detect the value of hepcidin 
as a marker of iron status in post renal transplant 
recipients as compared with chronic renal failure (CRF) 
patients on hemodialysis. 
Results: In our study we found the level of serum 
prohepcidin in the renal transplant recipient group to be 
comparable to the control group. In the group with CKD 
the serum prohepcidin was significantly lower than 
controls as well as the transplant recipients (p-value: 
0.00). There was no significant difference between the 
CKD group with higher hemoglobin and those with 
lower hemoglobin. From the correlation between the 
acute phase proteins and prohepcidin we found a positive 
correlation between serum ferritin, CRP and prohepcidin 
only in the group with CKD on hemodialysis.  
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Correspondence and offprint requests to: Dr. Mohamed El-Khatib, Internal 
Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt. 
Conclusion: We suggest that serum prohepcidin can be 
used as a routine measurement in transplant recipients as 
an indicator of the iron stores in the body. Further 
dedicated studies on large groups of patients need to be 




Body iron metabolism is based on a highly efficient 
system of iron conservation and recycling. Maintenance 
of body iron homeostasis requires mechanisms to control 
uptake and mobilization from stores to fulfill 
erythropoietic needs and to scavange used iron [1]. 
Recently major advances have been made in 
understanding the genetics of iron metabolism and this 
has led to identification of a number of new proteins 
involved in iron homeostasis. The discovery of hepcidin 
and subsequent research in the peptide has helped to 
provide a more functional view of iron metabolism and 
elucidate the mechanisms affecting iron status in patients 
with chronic inflammation and anemia [2]. 
Hepcidin is a 25 aminoacid peptide that is produced 
primarily by the liver in response to a variety of stimuli 
known to modulate tissue iron stores and its serum 
availability [3]. It circulates in plasma, filtered by the 
kidney, and accumulates in urine [4]. Hepcidin is 
synthesized as an 84 aminoacid prepropeptide which is 
subsequently processed into a 60-64 residue prohepcidin 
peptide and then finally into the mature biologically 
active 25 aminoacid hepcidin [5]. The presence of 
hepcidin in the plasma negatively regulates the egress of 
iron from the cells and macrophages, involved in 
transport of iron into the extracellular spaces [6]. 
Hepcidin binds to ferroportin 1 present on the cell 
surface leading to the ubiquitinization of ferroportin 1 
and the lysosomal degradation of both proteins [7]. The 
loss of ferroportin decreases iron flow into plasma from 
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absorptive enterocytes, from macrophages that recycle 
the iron of senescent erythrocytes and from hepatocytes 
that store iron there by lowering plasma iron 
concentration [8]. Deficient production of hepcidin 
causes systemic iron overload, whereas hepcidin excess, 
caused by many factors including inflammatory 
mediators as IL-6 leads to the development of 
hypoferrinemia and anemia of chronic disease [9]. 
Hepcidin has also been shown to be an acute phase 
reactant, increased by interleukin (IL)-6 and markedly 
induced by infection and inflammation [10].  
Anemia of inflammation is characterized by a 
normocytic normochromic anemia associated with 
abnormal iron utilization, erythropoietin 
hyporesponsiveness, decreased red blood cell survival. 
The increased serum ferritin –indicative of increased 
macrophage iron stores, and decreased serum iron 
transferrin saturation-indicative of decreased macrophage 
iron recycling, suggests a condition of hepcidin excess 
[11]. 
It has been progressively evident that currently available 
iron indices do not reliably identify iron limited 
erythropoeisis [12]. This condition is often a sequela of 
chronic inflammation and since chronic kidney disease 
(CKD) is considered an inflammatory status [12], and 
since hepcidin is eliminated by the kidney [13], 
documentation of the role of hepcidin in the development 
of anemia in chronic kidney disease and whether it can 
be used as a marker of iron status in CKD has been 
sought in many studies. 
Because hepcidin may convey important information 
about anemia and iron status, the aim of this study was to 
detect the value of hepcidin as a marker of iron status in 
post renal transplant recipients as compared with CRF 
patients on hemodialysis. 
 
Material and methods 
 
The patient population was selected from those who 
presented to the Hemodialysis Unit and the Renal 
Transplant Clinic, Cairo University, Faculty of Medicine 
Hospital, egypt. 
The study was conducted on 15 renal transplant 
recipients who performed the operation two years 
previously, 35 chronic kidney disease patients (CKD) on 
chronic hemodialysis, and 10 healthy individuals who 
acted as controls. 
The ethical committee of Cairo University approved the 
study and an oral consent was taken from all patients. 
They were divided into three groups: 
Group 1: Included 20 (CKD) patients on hemodialysis 
with a hemoglobin >10 gm/dl their age was 50.+/- 9.1. 
Group 2: Included 15 (CKD) patients on hemodialysis 
with a hemoglobin <10 gm/dl their age was 44.4+/-16.8. 
Group 3: Included 15 renal transplant recipients whose 
hemoglobin was > 10 gm/dl their age was 27.2 +/- 14.6. 
The patients underwent the transplant since 2 years and 
their creatinine ranged from 0.5-1.5. 
Group 4: Included 10 normal healthy volunteers their age 
was 37.6+/- 7.9. 
Exclusion criteria: Candidates that may affect iron status: 
 Acute hemorrhage  
 Pregnancy 
 Liver cirrhosis  
 Iron therapy 
 Patients receiving blood transfusion 
 Overt infections  
 
All patients underwent a complete clinical evaluation 
followed determination of the hemoglobin level, the iron 
status and C.reactive protein. 
 
Evaluation of iron status: 
 
Serum iron and TIBC were measured on Hitachi 917 
automated analyzer with kits purchased from Roche 
(Roche Diagnostics GmbH D-68298 Mannheim/ 
Germany). 
Serum transferrin and CRP concentration were 
determined using nephelometry technique on BN 
Prospec by kit supplied by Siemens (Siemens HealthCare 
Diagnostics 1717 Deerfield Road Deerfield IL60015-
0778) 
TSAt was calculated using the following equation. 
TSAt (%) = serum iron/transferrin x100. 
Serum ferritin was measured by chemiluminescent 
enzymatic immunometric assay on the Immulite 
Automated analyzer by kits supplied by DPC (Diagnostic 
products corporation 5700 West 96
th
 street Los Angeles, 
CA 90045-5597). 
Serum pro-hepcidin was measured using hepcidin 
prohormone enzyme linked immunosorbant assay 
(ELIZA) purchased from DRG (DRG instruments, 
Marburg Germany) which was used as an indirect 




Data obtained from the study was coded and entered 
using the software SPSS (Statistical package for social 
science) version11.0 Quantitative parametric data was 
summarized using mean and standard deviation, while 
non parametric was summarized as median and 
percentiles. Comparison between groups was done using 
t-test and Mann Whitney were used to compare two 
groups, while ANOVA and Kruskal Wallis test were 
used to compare multiple groups.  The correlation was 
done by Spearman‘s correlation coefficient. 




The mean serum level of Hepcidin was statistically 
significantly lower in the two CKD groups than those of 
the control group. It was statistically significantly higher 
in transplanted patients than that of the two CKD groups 
(P<0.01). 
The mean serum level of CRP was statistically 
significantly higher in the CKD cases with Hb <10 than 
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those of the control group. It was statistically 
significantly lower in Transplanted patients than that the 
CKD cases with Hb <10. 
The mean serum level of Hb are statistically significantly 
lower in the the two CKD groups than those of control. It 
was statistically significantly higher in Transplanted 
patients than that of the CKD cases with Hb <10. 
The mean serum level of total iron saturation are 
statistically significantly higher in the CKD cases with 
Hb <10 than those with Hb >10 and control. It was 
statistically significantly lower in transplanted patients 
than that of the CKD cases with Hb <10. 
The mean serum level of TIBC was statistically 
significantly lower in the CKD cases with Hb <10 than 
those with Hb >10 and control. It was statistically 
significantly lower in transplanted patients than that of 
the control, table 1. 
In the dialysis group, the CRP level showed statistically 
significant positive correlation with serum level of 
ferritin, and hepcidin levels (r=0.521, 0.611 and 
P<0.01respectively). Hepcidin level showed statistically 
significant positive correlation with serum level of 
ferritin (r=0.517and P<0.01) (table 2). 
Table 1. The descriptive characteristics and biochemical data in the four groups. 
 
 




Fig. 1. Mean Hepcidin levels in different groups. 
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Disease duration 11.0±0.4 13.8±4.5 8.9±4.7  0.034 
Hb, g/dl 13.0±1.8 11.9±1.4* 7.7±1.2*† 12.4±1.7*‡ 0.000 
Iron,ug/dl 66.7±23.2 68.2±29.1 73.9±36.2 79.4±36.7 0.709 
TIBC, ug/dl 398±116.5 232(194.2-357.7)* 163(149-219)*† 309(276-440) ‡ 0.000 
Transferrin saturation , % 17.8±6.5 24.6±8.3 40.7±21*† 25.9±15.5‡ 0.001 
Ferritin, ng/ml 40.5(16-206.9) 202(94.6-545.7) * 680(282-1085)*† 440(82-870)* 0.013 
Hepcidin, ng/ml 401.3±115.6 240.5±85.2* 300.9±93* 408.8±83.7†‡ 0.000 
CRP, mg/L 
 



















Fig. 2. Correlation between ferritin and hepcidin in chronic dialysis group. 
 
Correlations in transplantation group ferritin with CRP showed significant positive correlation (P=0.038), table 3.  
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The discovery in 2001, that the liver derived peptide 
hepcidin plays a central role in the regulation of body 
iron homeostasis was a major advance in that field [15]. 
Since then multiple studies have elucidated the various 
aspects of involvement of hepcidin in iron limited 
anemia and in iron overload states. The measurement of 
hepcidin and its relation to inflammation in particular has 
been of great clinical significance. The condition known 
as Anemia of chronic disease ACD has been recognized 
by clinicians for decades but its cause and how to avoid 
it has till recently baffled researchers. Patients with 
chronic kidney disease (CKD) suffer from anemia in the 
course of their illness whether they are on dialysis or not. 
The cause of anemia in these patients is multifactorial 
and recently the role of hepcidin has been widely 
investigated .In our study we investigated the level of 
prohepcidin in patients with CKD on hemodialysis with 
different levels of hemoglobin as well as post renal 
transplant recipients with normal renal functions. 
In our study we found the level of serum prohepcidin in 
the renal transplant recipient group to be comparable to 
the control group. In the group with CKD the serum 
prohepcidin was significantly lower than controls as well 
as the transplant recipients (p-value: 0.00). There was no 
significant difference between the CKD group with 
higher hemoglobin and those with lower hemoglobin. 
These findings were not consistent with other studies that 
found elevated levels of serum hepcidin in kidney 
allograft recipients, and attributed their findings to 
impaired renal functions and a low grade inflammatory 
state as reflected by hepcidin correlation with CRP, IL -6 
and ferritin [16]. These findings also do not agree with 
studies done on cases with CKD  that found a high level 
of serum hepcidin in CKD patients ,and attributed their 
findings to a state of chronic inflammation as well as 
decreased clearance of hepcidin by the kidney [12,17]. 
But, our findings agree with another study that found 
serum prohepcidin to be lower in anemia of chronic 
disease [18]. 
In our study we studied the parameters of iron indices in 
our three groups. We found no evidence of hypoferremia 
in any of our study groups and there were no significant 
differences between the groups and the controls or with 
each other. The level of the TIBC on the contrary 
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showed wide variations between the groups. In the renal 
transplant recipients the TIBC showed no significant 
difference with the controls and the transferrin saturation 
was normal. This is at variance with the group with CKD 
on hemodialysis whether their hemoglobin was above or 
below 10 g/dl. They had significantly lower TIBC than 
controls, despite the fact that their serum iron was within 
normal and comparable to the controls. The group with 
low hemoglobin had an even lower TIBC than the ones 
with higher hemoglobin and that was statistically 
significant (p-value: 0.00). The transferrin saturation in 
the CKD group was also within the normal range but 
showed significantly higher values in the group with 
lower hemoglobin levels. 
Iron status in patients with CKD exhibits wide variations. 
There are patients with absolute iron deficiency in which 
a low serum iron is accompanied by a low transferrin 
saturation and a low serum ferritin. This condition is 
usually due to chronic blood loss from the 
gastrointestinal tract or increased tendency to bleed due 
to platelet dysfunction [19]. It may also be due to loss of 
blood during hemodialysis or poor intake and/or 
absorption of iron [20]. Then there are patients with 
functional iron deficiency in which a low serum iron is 
accompanied by a low transferrin saturation and a high 
serum feritin. This is due to intense stimulation of RBC 
production by erythropoietin [19]. Lastly are the patients 
with a dramatic increase in serum ferritin along with a 
drop in transferrin saturation which is termed 
Reticuloendothelial blockade. This condition is common 
in patients on dialysis with low grade chronic 
inflammation .It is due to impaired release of iron from 
its storage sites [21]. 
In this study the serum ferritin in the transplant recipient 
group was significantly elevated when compared to 
controls (p value 0.01) but no significant difference with 
the CKD group, whose ferritin was also significantly 
more than the controls. The group with lower 
hemoglobin had a significantly higher ferritin than those 
with higher hemoglobin. 
Ferritin is the cellular storage protein for iron [22]. It is 
synthesized by the body as a protective mechanism to 
bind iron which is toxic to cells in various tissue 
compartments. It is also an acute phase reactant protein, 
the serum level of which will rise nonspecifically during 
infections and inflammation [23]. In the normal adult 
serum ferritin is usually about 12-30 ug/dl while in 
dialysis patients with normal iron stores it is usually 
below 100 ug/dl [24].  
In our transplant recipients the iron indices indicate a 
state of normal iron metabolism within the body. The 
exception is the serum ferritin. Renal transplantation is 
accompanied by endothelial dysfunction. In these 
patients, we found the CRP to be of normal value and yet 
there was a positive correlation between the ferritin and 
CRP in these patients. We summarize from this that 
elevated serum ferritin in these patients is not only an 
indicator of increased iron stores but may also be an 
acute phase reactant to chronic inflammation. 
In the group with CKD the iron parameters indicate a 
state of increased iron stores in the body. Patients with 
CKD have a chronic inflammatory state including an 
enhanced incidence of infections, elevated levels of 
proinflammatory cytokines and factors related to 
hemodialysis [25]. The level of the CRP in our patients 
with CKD and with lower hemoglobin was significantly 
elevated than controls or transplant recipients (p-value: 
0.03). There was a positive correlation between CRP and 
serum ferritin. An increasing attention has focused on 
inflammation as a cause of anemia in CKD [26]. From 
these findings we observe a condition of functional iron 
deficiency which was less pronounced in the patients 
with high hemoglobin than those with lower hemoglobin. 
The serum prohepcidin in the CKD group showed a 
significant correlation with ferritin and CRP. These 
findings are in concordance with other studies that found 
a strong correlation with ferritin, CRP or both [12,16,27]. 
The serum prohepcidin in the renal transplant recipients, 
in our study did not correlate with either ferritin or CRP.      
Residual renal function seems to play a pivotal role in 
hepcidin levels in dialyzed patients. In addition the 
presence of low grade inflammation is more pronounced 
in anuric patients [28]. This statement may explain the 
higher levels of prohepcidin, ferritin and CRP in CKD 
patients with more pronounced anemia. 
Despite the fact that our finding do not correlate with 
other studies approaching the same topic, we perceived 
from the data of our study that the serum prohepcidin 
was comparable to controls and did not correlate with 
parameters of inflammation, unlike the patients with 
CKD. Thus serum prohepcidin appears from this study to 
be a better indicator of the iron state than serum ferritin. 
We would like to recommend the routine measurement 
of serum prohepcidin or even better the level of serum 
hepcidin 25 in patients following renal transplantation as 
a marker of iron state in these patients. 
There are certain limitations to our study which are quite 
similar to other studies as the rather small number of 
patients in the study, the use of prohepcidin protein 
measurement instead of the hepcidin protein, and the fact 
that all patients were iron replete. 
In conclusion, serum hepcidin appears to be a missing 
link in the etiology of anemia of chronic diseases. It 
appears to be a reliable reflection of the iron status of the 
body and should be routinely measured in cases of 
anemia of iron deficiency. Therapies targeting the 
hepcidin gene or receptor should be sought with speed 





1. Finch C.: Regulators of iron balance in humans. Blood 1994; 84: 
1697-1702. 
2. Robson KJ.: Hepcidin and its role in iron absorption . Gut 2004; 
53: 617-619. 
3. Pigeon C., Ilyin G., Courselaud B. et al.L: A new mouse liver-
specific gene encoding a protein homologous to human 
antimicrobial peptide hepcidin, is overexpressed during iron 
overload.J Biol.Chem. 2001; 276: 7811-7819. 
  
51 
4. Pork CH., Vabre EV., Waring AJ., Ganz T.: Hepcidin a urinary 
antimicrobial peptide synthesized in the liver.J Biol. Chem. 2001; 
276: 7806-7810. 
5. Kemna EH., Tjalsma H., Willems HL., Swinkels OW.: Hepcidin: 
from discovery to differential diagnosis. Hematologica 2008; 93: 
90-97. 
6. Nicolas G., Bennoun M., Portea A et al.: Severe iron deficiency 
anemia in transgenic mice expressing liver hepcidin. Proc Natl 
Acad Sci USA 2002; 99: 4596-4601. 
7. De Domenico I., Ward DM., Langelie C. et al.: The molecular 
mechanism of hepcidin mediated ferroportin down regulation. 
Mol. Biol. Cell. 2007; 18:2567-2578. 
8. Nemeth E.: Targeting the hepcidin –ferroportin axis in the 
diagnosis and treatment of anemias. Adv. Hematol. 2010; 750643 
E pub 2009 Dec 24. 
9. Goswam T., Andrews NC.: Hereditary hemochromatosis protein 
HFE interaction with transferrin receptor 2 suggests a molecular 
mechanism for mammalian iron sensing .J boil. Chem. 2006; 
281(39): 28494-28498. 
10. Nemeth E., Tuttle MS., Powelson J. et al.: Hepcidin regulates iron 
efflux by binding to ferroportin and inducing its internalization. 
Science 2004; 306: 2090-2093. 
11. Roy CN., Mak HH., Akpan I. et al.:  Hepcidin antimicrobial 
peptide transgenic mice exhibit features of anemia of 
inflammation. Blood 2007; 109:4038-4044. 
12. Zaritsky J., Young B. Wang. H. et al.:  Hepcidin –A potential 
novel biomarker for iron status in chronic kidney disease J Am. 
Soc. Nephr. 2009; 4:1051-1056. 
13. Nemeth E., Rivera S., Gabayan V. et al.: IL-6 mediates 
hypoferremia in inflammation by inducing the synthesis of the 
iron regulatory hormone hepcidin J Clin. Invest. 2004; 113:1271-
1276. 
14. Frazer DM. and Anderson G.: Hepcidin compared with 
prohepcidin: An absorbing story. AM. J Clin. Nutr. 2009; 89:475-
476. 
15. Nicolas G., Bennoun M., Deavaux et al.:  Lack of hepcidin gene 
expression and severe tissue iron overload in upstream 
stimulatory factor 2 (USF2) knock out mice. Proc. Natl. Acad.Sci. 
USA 2001; 98:8780-8785. 
16. Malayszko J, Malyszko JS., Pawlak K., Mystiwiec M.: Hepcidin, 
an acute phase protein and a marker of inflammation in kidney 
transplant recipients with and without coronary artery disease. 
Transplant Proc. 2006; 38: 2895-2898. 
17. Tomosugi N., Kawabata H., Wakatabe R., et al.: Detection of 
serum hepcidin in renal failure and inflammation by using protein 
chip system Blood 2006; 168:1381-1387. 
18. Dallalio G., Fleury T., Means RT.Jr:   Serum hepcidin in clinical 
specimens Br. J Haematol 2003; 122: 996-1000. 
19. Fishbane S., Shapiro W., Dutka P. et al.:  A randomized trial of 
iron deficiency testing strategies in hemodialysis patients.  Kid. 
Int. 2001; 60 :2406-2410 
20. Besarab A., Amin N., Ahsan M. et al.: Optimization of epoetin 
therapy with intravenous iron therapy in hemodialysis  patients.  J 
Am. Soc. Nephr 2000; 11:530. 
21. Bailie GR., Clark JA., Lane PL.: Hypersensitivity reactions and 
deaths associated with intravenous iron preparations. Nephrol. 
Dial.Transplant 2005; 20:1443. 
22. Harrison PM., Arosio P.: The ferritins: Molecular properties iron 
storage function and cellular regulation  Biochim.Biophys. Acta. 
1996; 1275: 161-165. 
23. Torti FM., Torti SV.:  Regulation of ferritin genes and protein.  
Blood 2002; 99: 3505-3516. 
24. Van Wyck DB., Cavalla G.,Spinowitz BS. Et al. Safety and 
efficacy of iron sucrose in patients sensitive to iron dextran: North 
American Clinical Trial. Am. J Kidney Dis. 2000: 36: 88-92. 
25. Cappelli G., Tetta C., Canaud B.: Is boifilm a cause of silent 
inflammation in hemodialysis patients? A fascinating working 
hypothesis. Nephrol. Dial. Transplant, 2005; 20: 266-270. 
26. Poole S., Bird TA., Selkirk S. et al.:  Fate of injected interleukin 1 
in rats sequestration and degradation in the kidney Cytokine, 
1990; 2: 416-422. 
27. Nemeth E., Valone EV., Territo M, et al.: Hepcidin, a putative 
mediator of anemia of inflammation is a type II acute phase 
protein  Blood  2003;101:2461-2468. 
28. Malyszko J., Malyszko JB., KOzminski P., Mysliwiec M.:  Types 
of renal replacement therapy and residual renal function Ren.  
Fail.  2009; 31 :876-883. 
                        
